$P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.$

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.

Bibliographic Details
Main Authors:	Jozef Michalka, Jana Marková, Ľubica Gahérová, Mária Maco, Vít Procházka, Jan Kořen, Alice Sýkorová, Pavla Štěpánková, Kateřina Steinerová, Lekaa Mohammad, Juraj Ďuraš, Barbora Velacková, Tomáš Doležal, Kateřina Benešová, Marie Lukášová, Andrea Janíková, Zdeněk. Král., Heidi Móciková
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000890984.54786.aa

Similar Items

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
by: Heidi Mocikova, et al.
Published: (2022-10-01)

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
by: Heidi Mocikova, et al.
Published: (2022-05-01)

Brentuximab vedotin induced uveitis
by: Stijn Therssen, M.D., et al.
Published: (2022-06-01)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
by: Jana Marková, et al.
Published: (2022-10-01)

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
by: Vit Prochazka, et al.
Published: (2022-10-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Real experience of brentuximab vedotin for cutaneous T cell lymphomas
by: F. Keklik Karadag, et al.
Published: (2020-10-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
by: Rebecca L. Allchin, et al.
Published: (2020-12-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
by: Mustafa Şahin, et al.
Published: (2021-02-01)

Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report
by: Attilio Di Girolamo, et al.
Published: (2018-10-01)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
by: Ayana Uchimura, et al.
Published: (2022-03-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
by: E. La Spina, et al.
Published: (2020-09-01)

CD30 - the head of TNF-family… or a successful story of brentuximab vedotin
by: Popović Lazar, et al.
Published: (2013-01-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
by: Xudong Zhang, et al.
Published: (2023-12-01)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
by: Dayeeta Bera, et al.
Published: (2024-02-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
by: Ruxandra Irimia, et al.
Published: (2023-03-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Brentuximab Vedotin versus checkpoint inhibitors: Which one? When? Why should be preferred?
by: Murat Özbalak
Published: (2022-10-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

Brentuximab vedotin treatment for mycosis fungoides with CD30+ large‐cell transformation in the early stage
by: Shujiro Hayashi, et al.
Published: (2023-12-01)

Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis
by: Valeria Behle, et al.
Published: (2017-05-01)